Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Masimo Corporation - Common Stock (NQ:MASI)

166.97 -4.37 (-2.55%)
Streaming Delayed Price Updated: 11:25 AM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Masimo Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
How Do Investors Really Feel About Masimo?
Via Benzinga
Here's How Much You Would Have Made Owning Masimo Stock In The Last 10 Years
Via Benzinga
3 Unprofitable Stocks with Questionable Fundamentals
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital... 
Via StockStory
Reflecting On Patient Monitoring Stocks’ Q1 Earnings: Masimo (NASDAQ:MASI)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Masimo (NASDAQ:MASI) and the... 
Via StockStory
Topics Artificial Intelligence
Here's How Much $100 Invested In Masimo 15 Years Ago Would Be Worth Today
Via Benzinga
Is the Market Bullish or Bearish on Masimo?
Via Benzinga
Earnings Scheduled For May 6, 2025
Via Benzinga
Masimo's Earnings: A Preview
Via Benzinga
Is the Market Bullish or Bearish on Masimo?
Via Benzinga
MASI Q1 Earnings Call: Revenue Tops Expectations, Focus Shifts to Healthcare Core Amid Tariff Headwinds
Medical tech company Masimo (NASDAQ:MASI) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.5% year on year to $372 million. The company expects the full year’s... 
Via StockStory
Topics World Trade
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Masimo’s (NASDAQ:MASI) Q1: Beats On Revenue But Stock Drops
Medical tech company Masimo (NASDAQ:MASI) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 24.5% year on year to $372 million. The company expects the full... 
Via StockStory
Masimo (MASI) Q1 Earnings Report Preview: What To Look For
Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings tomorrow after market close. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga
Masimo Makes A Bullish Post-Earnings Move. Why One Analyst Is Cautious.
Future earnings growth could falter as Masimo makes steep cost reductions. 
Via Investor's Business Daily
$1000 Invested In Masimo 15 Years Ago Would Be Worth This Much Today
Via Benzinga
3 Healthcare Stocks Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
Intuitive Surgical Gets Rating Upgrade. No. 1 In Its Industry; Profits, Sales Climbing.
Intuitive Surgical, No. 1 stock in its group, has a deep moat around its technology and has sold is robotic surgical systems for 30 years. 
Via Investor's Business Daily
Topics Initial Public Offering
Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)
Let’s dig into the relative performance of Masimo (NASDAQ:MASI) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers. 
Via StockStory
Topics Artificial Intelligence
How Is The Market Feeling About Masimo?
Via Benzinga
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
$1000 Invested In Masimo 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Masimo (MASI): Buy, Sell, or Hold Post Q4 Earnings?
What a fantastic six months it’s been for Masimo. Shares of the company have skyrocketed 45.8%, hitting $167.70. This was partly due to its solid quarterly results, and the run-up might have investors... 
Via StockStory
3 Small-Cap Stocks in Hot Water
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest... 
Via StockStory
Topics Artificial Intelligence
Xpeng, Li Auto And Nutanix Are Among Top 12 Large-Cap Gainers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio?
These large-cap stocks were top performers last week. Heico, Xpeng, Li Auto, Lineage, Erie Indemnity, Lloyds, Unum, FICO, Masimo, Smith & Nephew, AB InBev, and Nutanix all saw significant gains. 
Via Benzinga
Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom... 
Via StockStory
Topics Artificial Intelligence
Why Is Masimo (MASI) Stock Soaring Today
Shares of medical tech company Masimo (NASDAQ:MASI) jumped 11.6% in the afternoon session after the company reported impressive fourth-quarter 2024 results, which beat analysts' revenue and EPS... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.